Compare WULF & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WULF | BIO |
|---|---|---|
| Founded | 1952 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.2B |
| IPO Year | 1999 | N/A |
| Metric | WULF | BIO |
|---|---|---|
| Price | $13.86 | $270.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | $17.96 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 30.6M | 291.7K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $168,455,000.00 | N/A |
| Revenue This Year | $139.73 | $2.51 |
| Revenue Next Year | $178.09 | $3.17 |
| P/E Ratio | ★ N/A | $9.72 |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $2.06 | $211.43 |
| 52 Week High | $18.51 | $343.12 |
| Indicator | WULF | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 39.31 |
| Support Level | $11.30 | $266.71 |
| Resistance Level | $16.76 | $290.01 |
| Average True Range (ATR) | 1.34 | 7.90 |
| MACD | -0.31 | 1.40 |
| Stochastic Oscillator | 2.00 | 47.08 |
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.